INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
EXPERT VIEW
EXPERT VIEW
Dr Carolina Dantas
THE IMPORTANCE OF THE BREATHING MANOEUVRE IN NEBULISED THERAPIES
Carolina Dantas and Ulf Krueger highlight the importance of the breathing manoeuvre in nebulised therapies – and describe a small study designed to test the effectiveness of patient feedback technology when it comes to guiding the inhalation manoeuvre.
EXPERT VIEW
Michael Astle
TRANSFORMING PHARMA MANUFACTURING TO DRIVE SUSTAINABILITY AND COST EFFICIENCY
Michael Astle, Gareth Jenkins and Edward Mayo explore current strategies to reduce carbon emissions and drive cost efficiency throughout the healthcare industry.
EXPERT VIEW
Will Morris
ENVIRONMENTAL DRIVERS FOR CHANGE IN DRUG DELIVERY DEVICES
Will Morris discusses the positive changes that have occurred when it comes to environmental sustainability in the medical industry, in the context of examining what more can be done.
EXPERT VIEW
Jimin Han
SHAPING A SUSTAINABLE BIOPHARMA INDUSTRY
Jimin Han delves into the intricate landscape of sustainability challenges within the biopharma industry and explores the innovative solutions that are steering drug development toward a greener future.
EXPERT VIEW
Paramesh Natarajan
HOW LIFECYCLE ASSESSMENT SUPPORTS INSIGHT-DRIVEN SUSTAINABLE DESIGN
Paramesh Natarajan, Shadi Bavar and Charlie Dean present the case for using screening lifecycle assessments to lead into more detailed targeted and comprehensive lifecycle assessments focused on the areas of greatest environmental impact, using a screening lifecycle assessment of a hypothetical body-worn injector as an example.
EXPERT VIEW
Tom Oakley
“A CHILD IS NOT A SMALL ADULT”: CHALLENGES AND SOLUTIONS IN DEVELOPING DRUG DELIVERY DEVICES FOR CHILDREN
Tom Oakley and Heather Jameson consider the main differences in developing therapies and drug delivery devices for children and babies when compared with adults.
EXPERT VIEW
David DeSalvo
IDENTIFYING AND OVERCOMING THE CHALLENGES OF INJECTABLE COMBINATION PRODUCT EVOLUTION
David DeSalvo considers some potential challenges that the rapid evolution of autoinjectors (and combination product injectables in general) raises, along with how the industry can successfully address this cycle of reinvention.
EXPERT VIEW
Roger Bohannan
INJECTING INNOVATIVE SOLUTIONS INTO CONNECTED DELIVERY DEVICES
Roger Bohannan discusses the capabilities and design challenges of connected drug delivery devices.
EXPERT VIEW
Dave Beckstoffer
INCORPORATING MOTION DESIGN AT EARLY STAGES OF WEARABLE INJECTOR DEVELOPMENT
Dave Beckstoffer discusses the often overlooked importance of including motion system design considerations from the very earliest stages of wearable injector development, and how doing so can reduce costs, shorten timelines and improve patient outcomes.
EXPERT VIEW
Matt Parker
DIRECTIONS FOR WEARABLE ON-BODY INJECTOR SYSTEMS AND BEYOND
Matt Parker, Karthik Chellappan and David Cottenden discuss the current state of play for large-volume injection and look into the challenges that on-body delivery systems currently in development will need to overcome to find success in a changing marketplace.
EXPERT VIEW
Malcolm Boyd
WOULD YOU LIKE TO GO LARGE? KEY CONSIDERATIONS FOR LARGE-VOLUME INJECTORS
Malcolm Boyd discusses the factors that need to be considered early in the development of large-volume injectors, which will have a major influence on the performance, usability and cost of a device.
EXPERT VIEW
Thomas James
REUSABLE WEARABLE INJECTORS: LESSONS FROM IN VITRO DIAGNOSTICS
Thomas James explores how insights from the development of successful in vitro diagnostic instruments can help guide the evolution of wearable injectors.
EXPERT VIEW
Phil Sampey
DFM & DFA: THE DIFFERENCES, BENEFITS AND HOW TO IMPLEMENT THEM
Phil Sampey discusses the principles associated with design-for-manufacture (DFM) and design-for-assembly (DFA) methodologies as applied to drug delivery device design, giving an overview of what each involves and key areas of focus to ensure that the full benefits of these approaches can be realised.
EXPERT VIEW
Matthew Burton
IMed Consultancy
ENTERING THE UK MARKET: A GUIDE FOR US MEDICAL DEVICES COMPANIES
Matthew Burton discusses the new EU Medical Device Registration and offers a guide for the UK Responsible Person within companies.
EXPERT VIEW
Dr Carolina Dantas
THE POTENTIAL OF CONNECTIVITY AND MONITORING IN MESH NEBULISERS
Carolina Dantas and Ulf Krueger review the current connectivity and remote monitoring capabilities in mesh nebulisers – and their potential to impact patients’ healthcare journeys and the clinical development of inhaled therapies.
EXPERT VIEW
Dan Lock
THE IRONIES OF AUTOMATION: LESSONS FOR REMOTE PATIENT MONITORING
Dan Lock considers how to overcome potential pitfalls and make the most of remote patient monitoring for the benefit of both patient care and clinical trials.
EXPERT VIEW
Dr Jonathan Cape
MODIFIED-RELEASE MICROSPHERES: MAXIMISING COATING INTEGRITY AND OPTIMISING RELEASE
Jonathan Cape discusses development considerations and workflows to select optimal enteric coat weights for modified release microspheres – balancing performance considerations with API stability and the excipient burden to patients.
EXPERT VIEW
Richard Ball
INCREASE PRODUCTION SUCCESS THROUGH TABLET DESIGN TECHNIQUES
Richard Ball considers the important features of tablet design and discusses its importance to the mass production of tablets.
EXPERT VIEW
Dr Jnanadeva Bhat
HARD CAPSULES: A HOLISTIC APPROACH FOR ORAL DRUG DELIVERY AND FORMULATION
Jnanadeva Bhat and Manali Dalvi discuss how advances in capsule technology as an oral drug delivery method have opened up new avenues for the development of more effective and patient-friendly drugs.
EXPERT VIEW
Timothy Bubb
ENSURING PATIENT SAFETY AMIDST MEDICAL DEVICE REGULATION DELAYS WITH PMS
Timothy Bubb discusses the five steps to setting up an effective post-market surveillance process.
EXPERT VIEW
Thomas James
DESIGNING FOR USABILITY IN EMERGENCY-USE COMBINATION PRODUCTS
Thomas James highlights the importance of early user engagement, as well as continuous refinement of information and workflow design, for efficient development of drug-device combination products for emergency use.
EXPERT VIEW
John Burke
TACKLING DESIGN CHALLENGES IN EMERGENCY-USE AUTOINJECTORS
John Burke considers the challenges that manufacturers need to overcome when designing emergency-use autoinjectors.
EXPERT VIEW
Deepu Asok
STRATEGIES FOR TEST METHOD VALIDATION OF DRUG DELIVERY PLATFORMS
Deepu Asok discusses the importance of test method validation for drug-device combination product development and how a common mistake is to design the validation process for a specific device rather than to accommodate the potential variety of a device platform.
EXPERT VIEW
Eugene Polini
MITIGATING CONTAINER CLOSURE INTEGRITY CHALLENGES FOR INJECTABLES
Eugene Polini discusses the importance of container closure for the parenteral drug market, including some of the consequences of compromised container closure and what steps manufacturers can take to ensure that primary packaging systems remain sealed for a product’s entire shelf life.
Prev
1
…
3
4
5
6
7
…
15
Next
Top
